Reflections on 6 Years: Why Did My Oncology Team Keep Me on Gemcitabine When the Tumour Grew From 6.7 cm to 10.4 cm?...

Understanding Your Oncology Team's Treatment Decisions: A Reflection on Gemcitabine Continuation

I can see you're reflecting on a significant and understandably frustrating aspect of your cancer journey—the decision to continue gemcitabine while your tumor grew. This is an important question that deserves a thoughtful, educational explanation of how oncologists think about treatment decisions.

How Oncologists Evaluate Treatment Response

When doctors continue a chemotherapy drug despite tumor growth, it's rarely a simple oversight. According to NCCN Guidelines for Pancreatic Cancer, oncologists consider multiple factors beyond just tumor size measurements:

1. Rate of Growth Matters

• A tumor growing from 6.7 cm to 10.4 cm over a specific timeframe tells doctors something important
• If growth is slower than expected without treatment, the drug may still be providing benefit
• Pancreatic cancer without any treatment typically progresses much more rapidly

2. Tumor Marker Trends (CA 19-9)

• Blood tumor markers can sometimes show treatment benefit even when imaging shows growth
• Stable or declining CA 19-9 levels alongside modest tumor growth can indicate the drug is working
• This is why your oncology team likely monitored your blood work closely

3. Overall Clinical Picture

• Your functional status (how well you're doing day-to-day)
• Absence of new metastases (spread to other organs)
• Stability in other areas while one tumor grows
• Your ability to tolerate the medication

4. The "Progression-Free Survival" Concept According to ASCO Guidelines, oncologists sometimes distinguish between:

• Radiographic progression (what shows on scans)
• Clinical progression (when the cancer is clearly winning and causing problems)

A tumor can grow modestly while the patient remains stable—and switching drugs carries its own risks.

Why Not Switch Immediately?

This is where the clinical reasoning gets complex. According to the Let's Win Pancreatic Cancer survivor stories, several patients experienced similar situations:

From Ed O'Connor's story: He continued gemcitabine and Abraxane for years with good results, then switched to maintenance therapy. His doctors adjusted based on overall response, not just one measurement.

From Maryanne Winchester's story: She had tumor markers that were "up and down but ultimately trended down" even during active treatment, and her doctors continued because the overall trajectory showed benefit.

The Risk-Benefit Calculation:

• Continuing a drug you're tolerating = known side effects you're managing
• Switching to a new drug = unknown side effects, potential for worse toxicity, loss of time if the new drug doesn't work better
• Some chemotherapy drugs work better in sequence (saving stronger options for later)

Questions to Reflect On With Your [ID removed]

Looking back at your treatment, these questions might help you understand the decision-making:

1. What were your CA 19-9 tumor marker levels during this period? Were they stable, rising, or falling? This often matters more than size alone.

2. Did your tumor grow steadily, or was there a period of stability followed by growth? The pattern matters—slow growth sometimes indicates partial response.

3. Were there new metastases (spread) during this time, or was the growth localized to the original tumor? New spread would typically trigger a treatment change faster.

4. How were you tolerating gemcitabine? If you were managing side effects well, switching to a more toxic regimen carries real risks.

5. What was your performance status? If you were doing well functionally, your team might have been more conservative about switching.

6. Were there clinical trial options discussed? Sometimes continuing a current drug while researching alternatives is the strategy.

What the Literature Shows

According to NCCN Guidelines, for unresectable pancreatic cancer:

• Gemcitabine monotherapy is a standard option for patients who cannot tolerate more aggressive regimens
• Continuation decisions are individualized based on tolerability and overall response
• "Response" includes not just tumor shrinkage but also stabilization and symptom control

The Let's Win Pancreatic Cancer stories show that many long-term survivors had periods where tumors grew while on treatment, yet they ultimately achieved good outcomes through persistence and treatment adjustments over time.

Questions to Ask Your Oncology Team (For Your Reflection)

If you're reviewing this with your medical team or considering a second opinion:

1. "Looking back at my scans from [dates], what was the growth rate of my tumor, and how did that compare to what you expected without treatment?"

2. "What were my CA 19-9 levels during the period when my tumor grew from 6.7 to 10.4 cm? Were they rising, stable, or falling?"

3. "Were there other factors—like my overall health, side effects, or clinical stability—that influenced the decision to continue gemcitabine rather than switch?"

4. "In retrospect, do you think the decision to continue was appropriate, or would you have made a different choice?"

5. "What would have been the alternative treatment options at that time, and what were the pros and cons of switching?"

The Bigger Picture

Six years into your journey is remarkable. The fact that you're here, reflecting thoughtfully on your care, suggests your team's overall strategy—whatever the specific decisions—has supported your survival. Sometimes the "right" decision isn't obvious in the moment, and tumor growth doesn't always mean treatment failure.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

---

If you'd like to share more details about your specific situation—your CA 19-9 trends, whether new metastases appeared, or how you were tolerating treatment—I can provide more targeted educational context about the decision-making process.